Business
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
Studies highlight findings in the use of (Z)-endoxifen to advance breast cancer treatment and prevention SEATTLE, Nov. 6, 2025 /PRNewswire/ -- Atossa
About this update from Atossa Therapeutics, Inc.
[{"type":"text","content":"\n Studies highlight findings in the use of (Z)-endoxifen to advance breast cancer treatment and prevention\n \n \n SEATTLE, Nov. 6, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (\"Atossa\" or the \"Company\"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, announces that four abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Antonio, TX.\n \n \n \n \n \n \n \n \"We continue to add to our body of clinical evidence. At SABCS 2025, we look forward to four poster presentations highlighting findings from studies evaluating the use of (Z)-endoxifen to advance breast cancer treatment and prevention,\" said Dr. Steven Quay, Atossa Therapeutics President and Chief Executive Officer.\n \n \n \n \n \n \n \n Poster Presentation Details:\n \n \n \n \n \n \n \n \n Title:\n \n \n \n \n Initial results from RECAST DCIS: Multicenter platform trial testing activesurveillance and novel endocrine therapy agents for DCIS management\n \n \n \n \n \n \n Date/Time: \n \n \n \n \n Thursday, December 11, 2025, 12:30pm - 2:00pm CT \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Title:\n \n \n \n \n Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot\n \n \n \n \n \n \n Date/Time:\n \n \n \n \n Thursday, December 11, 2025, 12:30pm - 2:00pm CT \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Title:\n \n \n \n \n (Z)-Endoxifen Maintains ERα Antagonist Function Against ESR1 Mutants viaInactive Conformation Stabilization and Reversal of Mutant ESR1-AssociatedTranscriptional Signatures\n \n \n \n \n \n \n Date/Time: \n \n \n \n \n Friday, December 12, 2025, 7:00am - 8:30am CT \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Title:\n \n \n \n \n A Randomized Phase 2 Non-Inferiority Trial of (Z)-Endoxifen + Goserelin vs Exemestane + Goserelin as Neoadjuvant Treatment forPremenopausal Women with ER+/HER2- Breast Cancer (EVANGELINE)\n \n \n \n \n \n \n Date/Time: \n \n \n \n \n Friday, December 12, 2025, 12:30pm - 2:00pm CT \n \n \n \n \n \n \n \n About Atossa Therapeutics\n \n Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative therapies for significant unmet needs in breast cancer. Atossa's strategy emphasizes disciplined capi...